Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 19/20 | 0.87 |
| ▸ | BLK | P51451 | 3/20 | 0.87 |
| ▸ | EGFR | P00533 | 2/20 | 0.70 |
| ▸ | HCK | P08631 | 1/20 | 0.68 |
| ▸ | SRC | P12931 | 1/20 | 0.68 |
| ▸ | BMX | P51813 | 1/20 | 0.68 |
| ▸ | JAK3 | P52333 | 1/20 | 0.68 |
| ▸ | ITK | Q08881 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21330613 | 1.00 | BTK (0.87) | BTKBLKEGFRHCKSRC | |
| SCHEMBL21330621 | 0.93 | BTK (1.00) | BTKBLKEGFRHCKSRC | |
| SCHEMBL20177280 | 0.93 | BTK (1.00) | BTKBLKEGFRHCKSRC | |
| SCHEMBL20177348 | 0.93 | BTK (1.00) | BTKBLKEGFRHCKSRC | |
| SCHEMBL21330648 | 0.90 | BTK (0.87) | BTKBLKEGFR | |
| SCHEMBL21330650 | 0.90 | BTK (0.87) | BTKBLKEGFR | |
| SCHEMBL17235689 | 0.90 | BTK (1.00) | BTKBLKEGFRHCKSRC | |
| SCHEMBL21330638 | 0.89 | BTK (0.87) | BTKBLKEGFRHCKSRC | |
| SCHEMBL21330642 | 0.89 | BTK (0.87) | BTKBLKEGFRHCKSRC | |
| SCHEMBL21330623 | 0.89 | BTK (0.87) | BTKBLKEGFRHCKSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3543239-B1 | SELECTIVE BRUTON'S TYROSINE KINASE INHIBITOR AND USE THEREOF | HANGZHOU HEALZEN THERAPEUTICS CO LTD (CN) | 2024-11-13 | — | — | EP | disclosed |
| US-10711006-B2 | Selective Bruton's tyrosine kinase inhibitor and use thereof | HANGZHOU HERTZ PHARMACEUTICAL CO., LTD. (CN) | 2020-07-14 | — | — | US | disclosed |
| US-10711006-B2 | Selective Bruton's tyrosine kinase inhibitor and use thereof | HANGZHOU HERTZ PHARMACEUTICAL CO., LTD. (CN) | 2020-07-14 | — | — | US | disclosed |
| CN-108069974-B | Selective Bruton tyrosine kinase inhibitor and application thereof | HANGZHOU HERTZ PHARMACEUTICAL CO., LTD. (CN) | 2019-12-10 | — | — | CN | disclosed |
| EP-3543239-A1 | SELECTIVE BRUTON'S TYROSINE KINASE INHIBITOR AND USE THEREOF | Hangzhou Hertz Pharmaceutical Co., Ltd. (CN) | 2019-09-25 | — | — | EP | disclosed |
| EP-3543239-A1 | SELECTIVE BRUTON'S TYROSINE KINASE INHIBITOR AND USE THEREOF | Hangzhou Hertz Pharmaceutical Co., Ltd. (CN) | 2019-09-25 | — | — | EP | disclosed |
| US-20190276461-A1 | SELECTIVE BRUTON'S TYROSINE KINASE INHIBITOR AND USE THEREOF | Hangzhou Healzen Therapeutics Co., Ltd. (CN) | 2019-09-12 | — | — | US | disclosed |
| US-20190276461-A1 | SELECTIVE BRUTON'S TYROSINE KINASE INHIBITOR AND USE THEREOF | Hangzhou Healzen Therapeutics Co., Ltd. (CN) | 2019-09-12 | — | — | US | disclosed |
| WO-2018090792-A1 | SELECTIVE BRUTON'S TYROSINE KINASE INHIBITOR AND USE THEREOF | 杭州和正医药有限公司 | 2018-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190276461-A1 | SELECTIVE BRUTON'S TYROSINE KINASE INHIBITOR AND USE THEREOF | BTK, BMX, KCNK10 | BTK 1/4885BLK 12/4885EGFR 467/4885 |
| US-10711006-B2 | Selective Bruton's tyrosine kinase inhibitor and use thereof | BTK, SYK, LYN | BTK 1/4885BLK 35/4885EGFR 189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.